2076975 2077203
최종편집 2024-06-24 07:03 (월)
Individual investors show strong interest in Samsung Biologics and Daewoong Pharmaceutical in the first half
상태바
Individual investors show strong interest in Samsung Biologics and Daewoong Pharmaceutical in the first half
  • Jaehoon SongㆍHyeokgi Lee, Newsmp
  • 승인 2023.07.07 12:34
  • 댓글 0
이 기사를 공유합니다

Individual net purchases, Samsung Biologics KRW 336.5 billionㆍDaewoong Pharmaceutical KRW 101.8 billion
Institutional investors drawn to CelltionㆍYuhan CorporationㆍHanmi Pharmaceutical

[Newsmp] Individual investors' net buying amount for Samsung Biologics, among the 47 pharmaceutical index components during the first half of the year, amounted to KRW 336.5 billion, the Korea Exchange said.

Daewoong Pharmaceutical exceeded KRW 101.8 billion, surpassing KRW 100 billion, while Green Cross, Daewon Pharmaceutical, Daewoong, Pharmicell, and Boryung Pharmaceutical also saw net purchases of KRW 45.1 billion, KRW 30.8 billion, KRW 16.2 billion, KRW 14.4 billion, and KRW 12.1 billion, resulting seven stocks to excel KRW 10 billion.

On the other hand, individuals net sold Hanmi Pharmaceutical for KRW102.8 billion, HanAll Biopharma for KRW 48.3 billion, SK Bioscience for KRW 45.4 billion, Celltrion for KRW 42.8 billion, and Yuhan Corporation for KRW 31.4 billion.

Moreover, individual investors' net selling amount for JW Pharmaceutical was KRW 13.2 billion, Il Dong Pharmaceutical was KRW 12.7 billion, Ilsung Pharmaceutical was KRW 10.4 billion, and Chong Kun Dang Pharmaceutical was KRW 10.3 billion, leading to a total net selling amount of KRW 100 billion for a total of nine stocks.

During the same period, institutional investors directed their focus toward Celltrion, Yuhan Corporation, and Hanmi Pharmaceutical. Institutions' net purchase amount for Celltrion touched KRW 140.4 billion, surpassing KRW 100 billion. Yuhan Corporation stood at KRW 55.9 billion, while Hanmi Pharmaceutical reached KRW 55.3 billion, surpassing KRW 50 billion.

Furthermore, institutional investors demonstrated a net buying amount exceeding KRW 10 billion for six stocks, including HanAll Biopharma at KRW 45.6 billion, SK Bioscience at KRW 37.0 billion, Ilsung Pharmaceutical at KRW 13.6 billion.

In contrast, institutions opted for net selling for Samsung Biologics, reaching a scale of KRW 211.7 billion, while also selling Daewoong Pharmaceutical for KRW 91.8 billion, Daewoong for KRW 21.9 billion, and Bionote for KRW 14.9 billion.

In the meantime, foreign investors recorded net purchase amounts exceeding KRW 10 billion for just two stocks, Hanmi Pharmaceutical at KRW 48.2 billion and Il Dong Pharmaceutical at KRW 13.8 billion.

In terms of net selling, foreign investors exceeded KRW 10 billion for five stocks. They sold Celltrion for KRW 255.4 billion, Samsung Biologics for 119.6 KRW billion, Green Cross for KRW 41.3 billion, Daewon Pharmaceutical for KRW 24.8 billion, Yuhan Corporation for KRW 24.2 billion, and Daewoong Pharmaceutical for KRW 10.2 billion.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.